GRI Bio (GRI) AI Stock Analysis

• Market Cap: $3.10M
• Dividend Yield: N/A
• Average Volume (3M): 333.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: N/A
• EPS Growth: 98.55%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -5.80
• Shares Outstanding: 2,347,272
• 10 Day Avg. Volume: 122,133
• 30 Day Avg. Volume: 333,421
• PEG Ratio: -1.15
• Price to Book (P/B): -204.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -305.62
• Enterprise Value/Market Cap: 107.53
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -9.00
• 1Y Price Target: $10.00
• Price Target Upside: 614.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: ―

GRI Bio's stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.

Positive Factors

Financial Position

GRI Bio has a solid financial foundation with enough cash to last into 2026, providing stability and confidence to investors.

Market Opportunities

The company's focus on diseases with large market potentials, like Idiopathic Pulmonary Fibrosis and autoimmune disorders, presents significant opportunities for growth.

Safety Profile

GRI-0621 is showing a favorable safety profile, which helps to de-risk upcoming data readouts and differentiates the molecule in its field.

Negative Factors

Clinical Trial Risks

Despite the potential rewards, there are high risks associated with clinical trials that could impact the company's progress and stock performance.

Dependence on Future Data

Future stock performance is highly dependent on the anticipated interim and top-line data from the Phase 2a study, which introduces uncertainty.

GRI Bio Business Overview & Revenue Model

Company Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

How the Company Makes Money

GRI Bio generates revenue through the development and commercialization of its proprietary therapies. The primary revenue streams include licensing agreements with pharmaceutical companies and potential milestone payments and royalties from successful drug candidates developed using their platform technology. Additionally, GRI Bio may engage in strategic partnerships and collaborations with other biotech firms to co-develop and market new therapies. The company's earnings are significantly influenced by its ability to advance drug candidates through clinical trials and secure regulatory approvals, as well as the establishment of lucrative partnerships with larger pharmaceutical entities.

GRI Bio Financial Statement Overview

Summary

GRI Bio shows progress in revenue and equity but faces profitability and cash flow challenges. The high operational costs and cash burn pose risks, despite a strong equity position.

Income Statement

GRI Bio's income statement shows some improvement in revenue from the previous year, with a TTM (Trailing-Twelve-Months) total revenue of $4.91 million, up from $0 in 2022. However, the company continues to face significant challenges in profitability, as indicated by negative net income and EBIT margins. The EBIT margin for the TTM is -103.5%, and the net profit margin is -167%, highlighting ongoing operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet reflects a stronger equity position, with stockholders' equity of $56.33 million as of the latest period, a recovery from previous negative equity figures. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage, which could be a positive factor in reducing financial risk. The equity ratio stands at 98.14%, showcasing a strong equity base relative to total assets, albeit with limited asset growth.

Cash Flow

GRI Bio's cash flow statement shows a negative operating cash flow and free cash flow in the TTM, with free cash flow at -$8.61 million. The operating cash flow to net income ratio is 1.05, suggesting the company is burning cash at a rate close to its net losses. Free cash flow growth remains negative, indicating ongoing challenges in generating cash from operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	100.00K
	Gross Profit
0.00	0.00	0.00	0.00	0.00
	EBIT
-8.23M	-11.39M	-2.24M	-1.06M	-4.79M
	EBITDA
-8.23M	-10.90M	-2.51M	-963.00K	-4.71M
	Net Income Common Stockholders
-8.21M	-13.04M	-3.22M	-1.56M	-4.82M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.03M	1.81M	9.00K	7.51M	109.00K
	Total Assets
5.74M	2.96M	383.00K	8.34M	955.00K
	Total Debt
119.00K	14.00K	673.00K	169.00K	336.00K
	Net Debt
-4.91M	-1.79M	664.00K	-3.53M	227.00K
	Total Liabilities
1.71M	2.70M	2.01M	2.52M	2.41M
	Stockholders Equity
4.03M	259.00K	-1.63M	5.82M	-1.45M
Cash Flow		Free Cash Flow
-8.61M	-9.15M	-1.09M	-8.31M	-3.71M
	Operating Cash Flow
-8.61M	-9.14M	-1.08M	-8.31M	-3.71M
	Investing Cash Flow
0.00	-8.00K	-3.00K	-3.84M	-2.00K
	Financing Cash Flow
11.83M	10.95M	1.01M	15.75M	-4.00K

GRI Bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRI, the sentiment is Neutral. The current price of 1.4 is above the 20-day moving average (MA) of 1.36, below the 50-day MA of 1.51, and below the 200-day MA of 8.04, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of 47.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GRI.

GRI Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
GRI	45 Neutral	$3.10M	―	-468.00%	―	―	98.55%
ONCO	33 Underperform	$3.05M	―	-171.37%	―	―	-97.16%
SLRX	30 Underperform	$1.57M	―	-300.16%	―	―	79.57%
PCSA	29 Underperform	$4.08M	―	-192.72%	―	―	56.26%
SCPX	23 Underperform	$551.25K	―	-174.06%	―	-10.75%	82.25%
VINC	15 Underperform	$1.44M	―	-431.29%	―	―	48.17%